The Fly | PPCB

Unique Mechanism of Action for Cancer Treatment: Propanc's lead candidate, PRP, utilizes a novel approach of proenzymes to induce differentiation and apoptosis in cancer cells, setting it apart from conventional chemotherapy and radiation therapies.

Targeting High Unmet Medical Needs: The company focuses on aggressive and hard-to-treat cancers such as pancreatic, ovarian, and colorectal cancer, areas with significant medical need and limited effective treatment options.

Proprietary Intellectual Property: Strong global patent protection for its proenzyme technology and lead drug candidate, PRP, secures its innovation and creates barriers to entry for potential competitors.

Clinical Trial Failure Risk: The success of Propanc's therapeutic candidates, particularly Pancrozin, depends on favorable outcomes from extensive and costly clinical trials, which may fail to demonstrate efficacy or safety.

Regulatory Approval Uncertainty: Even if clinical trials are successful, obtaining necessary marketing approvals from regulatory bodies such as the FDA or EMA is a lengthy, complex, and uncertain process with no guarantee of success.

Significant Funding Requirements: Propanc is a pre-revenue company that will require substantial additional capital to fund its research, development, and operational activities, and there is no assurance that such funding will be available on acceptable terms or at all.